We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Rofecoxib.
- Authors
Scott, L.J.; Lamb, H.M.
- Abstract
▴ Rofecoxib selectively inhibits cyclo-oxygenase-2 in a dose-dependent manner in humans. No significant inhibition of cyclo-oxygenase-1 is observed with rofecoxib up to doses of 1000mg. ▴ In 4 large double-blind randomised trials performed in patients with osteoarthritis, rofecoxib 12.5 and 25 mg/day significantly improved physical functioning, assessed using the Western Ontario and McMasters Universities Osteoarthritis Index and patient or investigator global assessment, compared with placebo. In addition, rofecoxib showed similar clinical efficacy to that observed with diclofenac 50mg 3 times daily, ibuprofen 800mg 3 times daily and nabumetone 1500mg once daily. ▴ Rofecoxib is also an effective analgesic in patients with primary dysmenorrhoea or postoperative dental pain and demonstrates similar analgesic efficacy to that of naproxen sodium and ibuprofen. ▴ Rofecoxib is generally well tolerated. The most common adverse events associated with rofecoxib are diarrhoea, headache, nausea and upper respiratory tract infection. ▴ There was a significantly lower incidence of upper-gastrointestinal adverse events (perforations, ulcers and bleeds) in patients with osteoarthritis receiving rofecoxib 12.5, 25 or 50 mg/day than in those receiving ibuprofen, diclofenac or nabumetone.
- Subjects
NONSTEROIDAL anti-inflammatory agents; GASTROINTESTINAL system
- Publication
Drugs, 1999, Vol 58, Issue 3, p499
- ISSN
0012-6667
- Publication type
Article
- DOI
10.2165/00003495-199958030-00016